|
1
|
Abdull Razis AF and Noor NM: Cruciferous
vegetables: Dietary phytochemicals for cancer prevention. Asian Pac
J Cancer Prev. 14:1565–1570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lenzi M, Fimognari C and Hrelia P:
Sulforaphane as a promising molecule for fighting cancer. Cancer
Treat Res. 159:207–223. 2014. View Article : Google Scholar
|
|
3
|
Clarke JD, Hsu A, Williams DE, Dashwood
RH, Stevens JF, Yamamoto M and Ho E: Metabolism and tissue
distribution of sulforaphane in Nrf2 knockout and wild-type mice.
Pharm Res. 28:3171–3179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Myzak MC, Karplus PA, Chung FL and
Dashwood RH: A novel mechanism of chemoprotection by sulforaphane:
Inhibition of histone deacetylase. Cancer Res. 64:5767–5774. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gasper AV, Al-Janobi A, Smith JA, Bacon
JR, Fortun P, Atherton C, Taylor MA, Hawkey CJ, Barrett DA and
Mithen RF: Glutathione S-transferase M1 polymorphism and metabolism
of sulforaphane from standard and high-glucosinolate broccoli. Am J
Clin Nutr. 82:1283–1291. 2005.PubMed/NCBI
|
|
6
|
Peng X, Zhou Y, Tian H, Yang G, Li C, Geng
Y, Wu S and Wu W: Sulforaphane inhibits invasion by phosphorylating
ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer
DU145 cells. Oncol Rep. 34:1565–1572. 2015.PubMed/NCBI
|
|
7
|
Futran AS, Link AJ, Seger R and Shvartsman
SY: ERK as a model for systems biology of enzyme kinetics in cells.
Curr Biol. 23:R972–R979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goulet AC, Chigbrow M, Frisk P and Nelson
MA: Selenomethionine induces sustained ERK phosphorylation leading
to cell-cycle arrest in human colon cancer cells. Carcinogenesis.
26:109–117. 2005. View Article : Google Scholar
|
|
9
|
Krishna-Subramanian S, Hanski ML,
Loddenkemper C, Choudhary B, Pagès G, Zeitz M and Hanski C: UDCA
slows down intestinal cell proliferation by inducing high and
sustained ERK phosphorylation. Int J Cancer. 130:2771–2782. 2012.
View Article : Google Scholar
|
|
10
|
Li C, Zhou Y, Peng X, Du L, Tian H, Yang
G, Niu J and Wu W: Sulforaphane inhibits invasion via activating
ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS
One. 9:e905202014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang TY, Chang GC, Chen KC, Hung HW, Hsu
KH, Sheu GT and Hsu SL: Sustained activation of ERK and
Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase
arrest and apoptosis in human non-small cell lung cancer A549
cells. Eur J Pharmacol. 663:17–26. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thomas W, Coen N, Faherty S, Flatharta CO
and Harvey BJ: Estrogen induces phospholipase A2 activation through
ERK1/2 to mobilize intracellular calcium in MCF-7 cells. Steroids.
71:256–265. 2006. View Article : Google Scholar
|
|
13
|
Liu Z, Yu X and Shaikh ZA: Rapid
activation of ERK1/2 and AKT in human breast cancer cells by
cadmium. Toxicol Appl Pharmacol. 228:286–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bacigalupo ML, Manzi M, Rabinovich GA and
Troncoso MF: Hierarchical and selective roles of galectins in
hepatocarcinogenesis, liver fibrosis and inflammation of
hepatocellular carcinoma. World J Gastroenterol. 19:8831–8849.
2013. View Article : Google Scholar :
|
|
15
|
Tang D, Zhang J, Yuan Z, Gao J, Wang S, Ye
N, Li P, Gao S, Miao Y, Wang D, et al: Pancreatic satellite cells
derived galectin-1 increase the progression and less survival of
pancreatic ductal adenocarcinoma. PLoS One. 9:e904762014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu MH, Hong HC, Hong TM, Chiang WF, Jin YT
and Chen YL: Targeting galectin-1 in carcinoma-associated
fibroblasts inhibits oral squamous cell carcinoma metastasis by
downregulating MCP-1/CCL2 expression. Clin Cancer Res.
17:1306–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kohrenhagen N, Voelker HU, Kapp M, Dietl J
and Kämmerer U: The expression of galectin-1 in vulvar neoplasia.
Anticancer Res. 30:1547–1552. 2010.PubMed/NCBI
|
|
18
|
Barrow H, Rhodes JM and Yu LG: The role of
galectins in colorectal cancer progression. Int J Cancer. 129:1–8.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu MH, Hong TM, Cheng HW, Pan SH, Liang
YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, et al:
galectin-1-mediated tumor invasion and metastasis, upregulated
matrix metalloproteinase expression, and reorganized actin
cytoskeletons. Mol Cancer Res. 7:311–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elola MT, Wolfenstein-Todel C, Troncoso
MF, Vasta GR and Rabinovich GA: Galectins: Matricellular
glycan-binding proteins linking cell adhesion, migration, and
survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fuertes MB, Molinero LL, Toscano MA,
Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW and Rabinovich
GA: Regulated expression of galectin-1 during T-cell activation
involves Lck and Fyn kinases and signaling through MEK1/ERK, p38
MAP kinase and p70S6 kinase. Mol Cell Biochem. 267:177–185. 2004.
View Article : Google Scholar
|
|
22
|
Wang L, Tian Z, Yang Q, Li H, Guan H, Shi
B, Hou P and Ji M: Sulforaphane inhibits thyroid cancer cell growth
and invasiveness through the reactive oxygen species-dependent
pathway. Oncotarget. 6:25917–25931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mokhtari RB, Kumar S, Islam SS,
Yazdanpanah M, Adeli K, Cutz E and Yeger H: Combination of carbonic
anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the
viability and growth of bronchial carcinoid cell lines. BMC Cancer.
13:3782013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pastorek M, Simko V, Takacova M, Barathova
M, Bartosova M, Hunakova L, Sedlakova O, Hudecova S, Krizanova O,
Dequiedt F, et al: Sulforaphane reduces molecular response to
hypoxia in ovarian tumor cells independently of their resistance to
chemotherapy. Int J Oncol. 47:51–60. 2015.PubMed/NCBI
|
|
25
|
Deschênes-Simard X, Gaumont-Leclerc MF,
Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette
FA, Saba-El-Leil MK, Meloche S, et al: Tumor suppressor activity of
the ERK/MAPK pathway by promoting selective protein degradation.
Genes Dev. 27:900–915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fulcher JA, Hashimi ST, Levroney EL, Pang
M, Gurney KB, Baum LG and Lee B: galectin-1-matured human
mono-cyte-derived dendritic cells have enhanced migration through
extracellular matrix. J Immunol. 177:216–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HJ, Do IG, Jeon HK, Cho YJ, Park YA,
Choi JJ, Sung CO, Lee YY, Choi CH, Kim TJ, et al: Galectin 1
expression is associated with tumor invasion and metastasis in
stage IB to IIA cervical cancer. Hum Pathol. 44:62–68. 2013.
View Article : Google Scholar
|
|
28
|
Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha
TZ, Feng YZ and Zhang K: Clinicopathological and prognostic
significance of galectin-1 and vascular endothelial growth factor
expression in gastric cancer. World J Gastroenterol. 19:2073–2079.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao XY, Chen TT, Xia L, Guo M, Xu Y, Yue
F, Jiang Y, Chen GQ and Zhao KW: Hypoxia inducible factor-1
mediates expression of galectin-1: The potential role in
migration/invasion of colorectal cancer cells. Carcinogenesis.
31:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Juszczynski P, Ouyang J, Monti S, Rodig
SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA and
Shipp MA: The AP1-dependent secretion of galectin-1 by Reed
Sternberg cells fosters immune privilege in classical Hodgkin
lymphoma. Proc Natl Acad Sci USA. 104:13134–13139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon S and Seger R: The extracellular
signal-regulated kinase: Multiple substrates regulate diverse
cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC
and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell
invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of
MMP-2. Carcinogenesis. 28:977–987. 2007. View Article : Google Scholar
|
|
33
|
Barondes SH, Cooper DN, Gitt MA and
Leffler H: galectins. Structure and function of a large family of
animal lectins. J Biol Chem. 269:20807–20810. 1994.PubMed/NCBI
|
|
34
|
Yun SP, Lee SJ, Jung YH and Han HJ:
galectin-1 stimulates motility of human umbilical cord
blood-derived mesenchymal stem cells by downregulation of
smad2/3-dependent collagen 3/5 and upregulation of NF-κB-dependent
fibronectin/laminin 5 expression. Cell Death Dis. 5:e10492014.
View Article : Google Scholar
|
|
35
|
Rizqiawan A, Tobiume K, Okui G, Yamamoto
K, Shigeishi H, Ono S, Shimasue H, Takechi M, Higashikawa K and
Kamata N: Autocrine galectin-1 promotes collective cell migration
of squamous cell carcinoma cells through up-regulation of distinct
integrins. Biochem Biophys Res Commun. 441:904–910. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Etulain J, Negrotto S, Tribulatti MV,
Croci DO, Carabelli J, Campetella O, Rabinovich GA and Schattner M:
Control of angiogenesis by galectins involves the release of
platelet-derived proangiogenic factors. PLoS One. 9:e964022014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Le Mercier M, Lefranc F, Mijatovic T,
Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R and
Mathieu V: Evidence of galectin-1 involvement in glioma
chemoresistance. Toxicol Appl Pharmacol. 229:172–183. 2008.
View Article : Google Scholar : PubMed/NCBI
|
